Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Equity Income (2018 - 2022)

Theravance Biopharma (TBPH) has disclosed Equity Income for 5 consecutive years, with $28.1 million as the latest value for Q2 2022.

  • On a quarterly basis, Equity Income changed N/A to $28.1 million in Q2 2022 year-over-year; TTM through Jun 2022 was $100.0 million, a N/A change, with the full-year FY2021 number at $104.0 million, up 51.94% from a year prior.
  • Equity Income was $28.1 million for Q2 2022 at Theravance Biopharma, up from $25.1 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $30.2 million in Q3 2021 to a low of $686000.0 in Q1 2018.
  • A 5-year average of $13.3 million and a median of $12.7 million in 2019 define the central range for Equity Income.
  • Peak YoY movement for Equity Income: surged 808.02% in 2019, then grew 22.43% in 2021.
  • Theravance Biopharma's Equity Income stood at $5.4 million in 2018, then skyrocketed by 119.47% to $11.9 million in 2019, then surged by 69.05% to $20.1 million in 2020, then skyrocketed by 50.0% to $30.2 million in 2021, then decreased by 6.89% to $28.1 million in 2022.
  • Per Business Quant, the three most recent readings for TBPH's Equity Income are $28.1 million (Q2 2022), $25.1 million (Q1 2022), and $30.2 million (Q3 2021).